Article info

Download PDFPDF
Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis

Authors

  1. Correspondence to Dr Hiroki Masuda, Neurology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan; hiroki_masuda{at}chiba-u.jp
View Full Text

Citation

Masuda H, Mori M, Kuwabara S
Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis

Publication history

  • Received June 28, 2021
  • Accepted July 4, 2021
  • First published October 19, 2021.
Online issue publication 
November 16, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.